You have free access to this content

The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma

  1. B. Davidson

Article first published online: 30 NOV 2010

DOI: 10.1111/j.1365-2303.2010.00829.x

Issue

Cytopathology

Cytopathology

Volume 22, Issue 1, pages 5–21, February 2011

Additional Information

How to Cite

Davidson, B. (2011), The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma. Cytopathology, 22: 5–21. doi: 10.1111/j.1365-2303.2010.00829.x

Author Information

  1. Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

*Professor B. Davidson, Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Montebello N-0310 Oslo, Norway Tel.: 47-22934871; Fax: 47-22934871; E-mail: bend@medisin.uio.no

Publication History

  1. Issue published online: 11 JAN 2011
  2. Article first published online: 30 NOV 2010
  3. Accepted for publication 19 October 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (416K)

Keywords:

  • cytology;
  • malignant mesothelioma;
  • serous carcinoma;
  • effusion;
  • diagnosis;
  • cancer biology

B. Davidson

The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma

Malignant mesothelioma and ovarian/peritoneal serous carcinoma are two of the most common tumours affecting the serosal cavities. Unlike other malignant tumours diagnosed at this anatomical site, such as lung and breast carcinoma, malignant mesothelioma and serous carcinoma share a common histogenesis, may be difficult to differentiate morphologically, and co-express many of the diagnostic markers used by cytopathologists in effusion diagnosis. Selected markers have nevertheless shown sufficient sensitivity and specificity to differentiate serous carcinoma from malignant mesothelioma effectively. Recently, our group applied high throughput technology to the identification of new markers that may aid in differentiating these two cancer types and validated several of these markers in follow-up studies. This review will present current data regarding the diagnostic and biological aspects of malignant mesothelioma and ovarian/peritoneal serous carcinoma.

View Full Article (HTML) Get PDF (416K)